The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Jazz Pharmaceuticals

  • JAZZ
  • NASDAQ
  • Consumer Products
  • Latest 162.92
  • Currency US$
  • Change 0.21
  • Percent Change 0.129 %
  • Volume 668,820
  • Fri Aug 29, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 162.88
  • Previous Close 162.71
  • High 163.99
  • Low 160.49
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High02/25 176.601
  • 52-week Low10/08 80.40
  • Beta 0.656
  • Market Cap 9,464.02M
  • EPS 7.16
  • P/E 22.754
  • Forward P/E 17.54
  • PEG 0.99
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $923,100,000
  • Earnings $80,240,000
  • Return on Equity 6.26%

Cash Flow

  • Cash Flow --
  • Cash $245,870,000
  • Current Ratio 2.17

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $3,196,430,000
  • Liabilities $1,929,920,000
  • Liabilities-to-Equity Ratio 1.52

Price Ratios

  • Price to Sales 10.25
  • Price to Book 7.47
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Aug 5 n/a Nov 4 $1.98
Surprises Feb 25 -7.88% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Sep 01, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.

Related Securities
Symbol Type Latest % Chg

Officers

  • Bruce C. Cozadd Chairman; C.E.O. and Director
  • Kathryn E. Falberg Executive V.P. and C.F.O.
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

4TH FLOOR CONNAUGHT HOUSE ONE
DUBLIN, L2
4

Phone: (353)-1634-7800

investorinfo@jazzpharma.com
www.jazzpharma.com

Ideas & Discussion

Live Discussion of JAZZ on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.